184 related articles for article (PubMed ID: 32615946)
1. Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
Ruhnau J; Parczyk J; Danker K; Eickholt B; Klein A
BMC Cancer; 2020 Jul; 20(1):617. PubMed ID: 32615946
[TBL] [Abstract][Full Text] [Related]
2. Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines.
Parczyk J; Ruhnau J; Pelz C; Schilling M; Wu H; Piaskowski NN; Eickholt B; Kühn H; Danker K; Klein A
BMC Cancer; 2021 Apr; 21(1):481. PubMed ID: 33931028
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.
Duarte D; Cardoso A; Vale N
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299028
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
5. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells.
Haugrud AB; Zhuang Y; Coppock JD; Miskimins WK
Breast Cancer Res Treat; 2014 Oct; 147(3):539-50. PubMed ID: 25212175
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Schwartz DL; Bankson JA; Lemos R; Lai SY; Thittai AK; He Y; Hostetter G; Demeure MJ; Von Hoff DD; Powis G
Mol Cancer Ther; 2010 Jul; 9(7):2057-67. PubMed ID: 20587661
[TBL] [Abstract][Full Text] [Related]
8. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
9. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
10. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
11. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with auranofin and nutlin-3a induces synergistic cytotoxicity in breast cancer cells.
Ye DJ; Kwon YJ; Baek HS; Cho E; Kwon TU; Chun YJ
J Toxicol Environ Health A; 2019; 82(10):626-637. PubMed ID: 31258040
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
15. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
16. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW
Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Duarte D; Vale N
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769414
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways.
Nieves-Neira W; Pommier Y
Int J Cancer; 1999 Jul; 82(3):396-404. PubMed ID: 10399957
[TBL] [Abstract][Full Text] [Related]
19. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
20. Combined use of arginase and dichloroacetate exhibits anti-proliferative effects in triple negative breast cancer cells.
Verma A; Lam YM; Leung YC; Hu X; Chen X; Cheung E; Tam KY
J Pharm Pharmacol; 2019 Mar; 71(3):306-315. PubMed ID: 30362115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
